Teva- Pharmaceutical Industries Ltd. - ADR

Strong Revenue Growth: Teva reported robust revenue of $16.5 billion for 2024, marking a 9% increase year-over-year (YOY). This growth was driven primarily by innovative products AUSTEDO (34% growth), AJOVY (18% growth), and UZEDY (exceeding $100 million in revenue by reaching $117 million), showcasing effective execution on their growth strategy.

Innovative Product Forecasts: For 2025, Teva aims for significant contributions from its key products, projecting AUSTEDO revenues to be between $1.9 billion to $2 billion, AJOVY over $600 million, and UZEDY $160 million. This indicates confidence in continuing momentum in their innovative drug portfolio.

Earnings and EBITDA Expectations: The non-GAAP earnings per share (EPS) is forecasted at $2.35 to $2.65 for 2025, with non-GAAP adjusted EBITDA expected between $4.5 billion and $5 billion. However, this is not anticipated to significantly improve from 2024 levels, indicating potential operational challenges despite revenue growth.